Answering Critical Research Questions in Multiple Myeloma

In a recent video interview with Applied Clinical Trials, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation (MMRF), discussed challenges in multiple myeloma clinical trials, including inefficiency, lack of focus on critical patient questions, and underrepresentation of diverse patient populations. Andreini also highlighted the Horizon clinical trial and how MMRF is working to address unmet need in the myeloma research space.

ACT: What unmet needs or unanswered research questions is the Horizon trial hoping to address?

Andreini: In the myeloma field, there are now 15 plus approved therapies for patients, and that's an amazing thing, right? There's been so much progress to date. However, with so many drugs available now, it's increasingly complex to determine what are the optimal drug combinations, sequencing approaches, and dosing schedules for each and every patient, so there's a tremendous need, therefore, to have more efficient and focused clinical trials to help answer these types of questions. Our first platform as part of our Horizon clinical trials program is focused in relapse and refractory disease, because that is certainly an area of great unmet need for patients, but also we plan on opening a second platform later this year in high risk newly diagnosed disease, because we know also that these patients don't do well on standard of care and need new options.